Abstract 816P
Background
Based on two randomized trials (LACE and LAP2) minimal invasive surgery has turned into surgical standard in early stage endometrial cancer (EC) including “high-risk” patients. These recommendations are predominately based on “low-risk” cancers, which were mainly represented in both trial collectives. We herein provide a retrospective study focusing on potential differences in clinical outcome in early stage endometrioid ECs treated by laparoscopy or open surgery.
Methods
420 early stage ECs were retrospectively dichotomized according to the surgical approach and correlated to recurrence rate and clinical outcome. In addition, subgroup analyses were performed according relevant clinical risk parameters, namely FIGO stage, grading and LVSI.
Results
The analyzed collective consisted of 73.8% stage IA, 19.5% stage IB, and 6.7% stage II cases. 23% of patients exhibit G3 tumors and LVSI was detected in 12.4%. Minimal invasive surgery was performed in 54.5% of study patients. During a median follow-up of 5.0 years, recurrence or death were observed in 8.3% and 6.7%, respectively. Recurrences were located in the vaginal cuff (60.0%), in locoregional lymph nodes (31.4%), and in 8.6% in both sides. No distant metastases were observed. Under consideration of the mentioned clinicopathologic parameters, surgical approach in FIGO stage I did not influence recurrence rate and survival. However, in stage II disease, a laparoscopic approach was clearly associated with a higher recurrence rate (85.7% vs. 14.3%; p = 0.013). All recurrences were located in the vaginal cuff, and in one case, additional relapse was found in loco-regional lymph nodes. Moreover, laparoscopy in stage II disease was associated with impaired progression-free and overall survival (HR 8.86 (1.01 – 20.85) and HR 6.36 (1.10 – 28.61)).
Conclusions
We herein demonstrate that a laparoscopic approach in stage II endometrial cancer is associated with higher recurrence rates and impaired clinical outcome. These data could be interpreted in line with results of the LACC trial in cervical cancer. Although, grounded on a retrospective analysis, these hypothesis-generating results warrants a confirmatory trial, which is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Innsbruck Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11